Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Accounts Payables (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Accounts Payables data on record, last reported at $2.4 million in Q1 2026.

  • On a quarterly basis, Accounts Payables rose 62.57% to $2.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.4 million, a 62.57% increase, with the full-year FY2025 number at $1.6 million, up 36.77% from a year prior.
  • Accounts Payables reached $2.4 million in Q1 2026 per FULC's latest filing, up from $1.6 million in the prior quarter.
  • Over the last five years, Accounts Payables for FULC hit a ceiling of $6.0 million in Q1 2022 and a floor of $1.2 million in Q4 2024.
  • A 5-year average of $3.2 million and a median of $3.6 million in 2023 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: tumbled 60.93% in 2025, then soared 62.57% in 2026.
  • Tracing FULC's Accounts Payables over 5 years: stood at $3.6 million in 2022, then dropped by 24.22% to $2.8 million in 2023, then plummeted by 57.78% to $1.2 million in 2024, then skyrocketed by 36.77% to $1.6 million in 2025, then surged by 53.89% to $2.4 million in 2026.
  • Business Quant data shows Accounts Payables for FULC at $2.4 million in Q1 2026, $1.6 million in Q4 2025, and $2.9 million in Q3 2025.